Long-acting amylin analog (obesity / diabetes)
Amylin is a pancreatic peptide hormone that plays an important role in decreasing food intake and in the regulation of postprandial plasma glucose levels. The compound is a long-acting analog of amylin and it has demonstrated significant weight loss in pre-clinical models of obesity.
2018 achievements and next steps
The once-weekly amylin analog lead molecule for treatment of diabetes/obesity was replaced by a stronger back-up candidate with improved pharmaceutical properties. Phase 1 clinical testing is anticipated to start in 2019.
The global prevalence of obesity has more than doubled since 1980. In 2014, more than 1.9 billion adults were classified as overweight and over 600 million of these were obese.*
Collaboration with Boehringer Ingelheim
Zealand has two collaborations with Boehringer Ingelheim, where they funds all research, development and commercialization activities. Zealand is eligible to receive royalties and milestone payments as follows:
Long-acting amylin analog (2014 agreement)
Initiation of Phase 1 trial triggered a milestone payment of EUR 4 million to Zealand
EUR 283 million outstanding in milestone payments
Mid single-digit to low double-digit percentage royalties on global sales